Home> Products> 0 3mg

{ "products": [ { "_id": "66d83ad4ed345980e0fca5c5", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Voglibose (0.3mg), Metformin (500mg), Gliclazide (80mg)", "description": "GLICLAGLAZE TRIO 0.3 \nVoglibose (0.3mg), Metformin (500mg), Gliclazide (80mg)\nGLICLAGLAZE TRIO 0.3 is a powerful combination medication designed to manage and control type 2 diabetes. It is formulated with three active ingredients: Voglibose, Metformin, and Gliclazide. This unique combination helps to regulate blood sugar levels effectively, providing a comprehensive approach to diabetes management. GLICLAGLAZE TRIO 0.3 is particularly useful for patients who require a multifaceted treatment strategy to keep their blood glucose levels in check.\n\n \n\nKey Benefits:\n \n\nEffective Blood Sugar Control: The combination of Voglibose, Metformin, and Gliclazide offers a synergistic effect, providing comprehensive control over blood sugar levels.\nPrevents Post-Meal Sugar Spikes: Voglibose helps in delaying glucose absorption, reducing the risk of hyperglycemia after meals.\nImproved Insulin Sensitivity: Metformin enhances the body's response to insulin, ensuring better glucose management.\nEnhanced Insulin Secretion: Gliclazide helps in stimulating insulin release from the pancreas, making it easier to maintain stable blood sugar levels.\n \n\nHow Does It Work?\n \n\nGLICLAGLAZE TRIO 0.3 works through a multi-pronged approach to manage diabetes. Voglibose slows down the absorption of carbohydrates in the gut, which helps to prevent rapid increases in blood sugar levels after meals. Metformin reduces the liver's glucose production and improves insulin sensitivity, ensuring better glucose uptake and utilization. Gliclazide stimulates the pancreas to release insulin, aiding in the reduction of blood glucose levels.\n\n \n\nDirections for Use:\n \n\nTake GLICLAGLAZE TRIO 0.3 as prescribed by your healthcare provider. It is typically taken before meals to maximize its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet. Your doctor will determine the appropriate dosage and frequency based on your individual health needs.\n\n \n\nSide Effects:\n \n\nLike all medications, GLICLAGLAZE TRIO 0.3 may cause some side effects. Common side effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Hypoglycemia (low blood sugar) may occur, especially if you skip meals or engage in intense physical activity. Other possible side effects include dizziness, headache, and fatigue. If you experience any severe side effects or allergic reactions, seek medical attention immediately.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 185.0, "discountamount": 56.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Key Benefits", "abdominal pain", "glucose uptake", "type 2 diabetes", "rapid increases", "insulin release", "low blood sugar", "GLICLAGLAZE TRIO", "medical attention", "glucose absorption", "allergic reactions", "appropriate dosage", "synergistic effect", "unique combination", "glucose production", "glucose management", "diabetes management", "healthcare provider", "severe side effects", "Common side effects", "blood glucose levels", "comprehensive control", "multi-pronged approach", "comprehensive approach", "Post-Meal Sugar Spikes", "individual health needs", "three active ingredients", "intense physical activity", "stable blood sugar levels", "Enhanced Insulin Secretion", "Other possible side effects", "Improved Insulin Sensitivity", "gastrointestinal disturbances", "Effective Blood Sugar Control", "powerful combination medication", "multifaceted treatment strategy", "postprandial blood sugar spikes" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1962, "imageuri": "https://productimages.withfloats.com/actual/66d83afac7293b3595ec4ea6.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/66d83afac7293b3595ec4ea6.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-04T10:47:48.369Z", "updatedon": "2024-09-04T10:47:48.369Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/voglibose-0-3mg-metformin-500mg-gliclazide-80mg-/1962", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE TRIO 0.3 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662cd3e870e7b20c49e689e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD G3 M0.3 ", "description": "VOGLIGOLD G3 M0.3 \nVoglibose 0.3 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg\nIntroduction to VOGLIGOLD G3 M0.3\nVOGLIGOLD G3 M0.3 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains three active ingredients: Voglibose 0.3mg, Glimepiride 3mg, and Metformin Hydrochloride 500mg. This multi-action formula targets different aspects of glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVoglibose 0.3mg\nVoglibose is an alpha-glucosidase inhibitor that works by:\n\nSlowing Carbohydrate Absorption: Voglibose inhibits the alpha-glucosidase enzyme in the small intestine, delaying the breakdown of complex carbohydrates into glucose. This helps to smooth out postprandial (after-meal) blood glucose peaks.\nGlimepiride 3mg\nGlimepiride is a sulfonylurea that helps control blood sugar by:\n\nStimulating Insulin Secretion: Glimepiride stimulates the pancreas to release more insulin, which helps lower blood sugar levels, particularly after meals.\nMetformin Hydrochloride 500mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReducing Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproving Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreasing Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nBenefits of VOGLIGOLD G3 M0.3\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Voglibose, Glimepiride, and Metformin effectively manages both fasting and postprandial blood sugar levels.\nEnhanced Insulin Secretion and Sensitivity: Glimepiride enhances insulin secretion, while Metformin improves insulin sensitivity, and Voglibose slows carbohydrate absorption.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: The risk of hypoglycemia is minimized due to the complementary actions of the three components.\nWeight Neutrality: Metformin and Voglibose are generally weight neutral, making this combination favorable for patients concerned about weight gain associated with diabetes medications.\nHow to Use VOGLIGOLD G3 M0.3\nDosage and Administration\nRecommended Dosage: The typical dosage is one tablet taken once or twice daily, as prescribed by your healthcare provider.\nAdministration: Take the tablet with meals to reduce gastrointestinal side effects and enhance the absorption of Metformin. Swallow the tablet whole with a glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD G3 M0.3 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vogligold-g3-m0-3-134319", "price": 185.0, "discountamount": 55.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "meal", "diet", "Order", "glass", "water", "EMAIL", "liver", "adults", "amount", "Fasting", "readings", "patients", "pancreas", "Low Risk", "exercise", "breakdown", "same time", "biguanide", "Decreasing", "one tablet", "Guidelines", "Glimepiride", "Adjustments", "weight gain", "information", "utilization", "Optimal Use", "best results", "Introduction", "sterispharma", "sulfonylurea", "Hypoglycemia", "muscle cells", "sterisonline", "CALL/WHATSAPP", "Voglibose 0.3", "Administration", "typical dosage", "glucose uptake", "treatment plan", "Consistent Use", "Key Components", "small intestine", "glycemic control", "three components", "VOGLIGOLD G3 M0.3", "different aspects", "Weight Neutrality", "several mechanisms", "glucose regulation", "Regular monitoring", "Recommended Dosage", "blood glucose peaks", "Insulin Sensitivity", "healthcare provider", "diabetes medications", "effective management", "multi-action formula", "complex carbohydrates", "Intestinal Absorption", "complementary actions", "gastrointestinal tract", "combination medication", "Metformin Hydrochloride", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "three active ingredients", "type 2 diabetes mellitus", "Enhanced Insulin Secretion", "Additional Health Benefits", "Hepatic Glucose Production", "alpha-glucosidase inhibitor", "gastrointestinal side effects", "Postprandial Glucose Management", "postprandial blood sugar levels", "comprehensive blood sugar control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1519, "imageuri": "https://productimages.withfloats.com/actual/667d30b6c303c6d6ad136ea4.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d30b6c303c6d6ad136ea4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T09:05:02.904Z", "updatedon": "2024-06-27T09:28:16.215Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vogligold-g3-m0-3-/1519", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD G3 M0.3 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 3mg+metformin 500mg+voglibose 0.3 mg", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662cb8e161afa2274ff6309", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD 0.3 ", "description": "VOGLIGOLD 0.3 \nVoglibose (0.3mg)\nIntroduction to VOGLIGOLD 0.3\nVOGLIGOLD 0.3 is an oral medication designed to help manage type 2 diabetes mellitus by controlling blood sugar levels. It contains Voglibose, an alpha-glucosidase inhibitor that works by slowing the digestion and absorption of carbohydrates in the intestines. This mechanism helps prevent spikes in blood sugar levels after meals. VOGLIGOLD 0.3 is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Component and Mechanism of Action\nVoglibose 0.3mg\nVoglibose is a potent alpha-glucosidase inhibitor. It functions by inhibiting the alpha-glucosidase enzyme in the small intestine, which is responsible for breaking down complex carbohydrates into simple sugars. By inhibiting this enzyme, Voglibose slows down the conversion of carbohydrates into glucose, thereby reducing the postprandial (after-meal) rise in blood sugar levels.\n\nSlows Carbohydrate Absorption: By delaying the absorption of glucose, Voglibose helps to smooth out the postprandial blood glucose peaks.\nReduces Postprandial Hyperglycemia: It specifically targets the blood sugar spikes that occur after meals, making it an effective treatment for controlling postprandial hyperglycemia.\nBenefits of VOGLIGOLD 0.3\nEffective Postprandial Blood Sugar Control\nManages After-Meal Blood Sugar Levels: VOGLIGOLD 0.3 helps to manage and reduce the rise in blood sugar levels that occur after meals.\nComplementary Therapy: It can be used in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin to provide comprehensive glycemic control.\nAdditional Health Benefits\nWeight Neutral: Voglibose is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nLow Risk of Hypoglycemia: When used alone, Voglibose has a low risk of causing hypoglycemia (low blood sugar), as it does not increase insulin secretion directly.\nHow to Use VOGLIGOLD 0.3\nDosage and Administration\nRecommended Dosage: The typical dosage of VOGLIGOLD 0.3 is one tablet taken three times a day, just before meals.\nAdministration: Take the tablet whole with a glass of water, just before starting your meal. This timing ensures that the medication works effectively by inhibiting the enzyme responsible for carbohydrate digestion.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD 0.3 regularly at the same times each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/st-gliptin-dapa-100-10-134075", "price": 119.0, "discountamount": 35.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "dapa", "rise", "diet", "Order", "water", "EMAIL", "meals", "glass", "option", "timing", "Action", "adults", "gliptin", "patients", "exercise", "readings", "Low Risk", "metformin", "VOGLIGOLD", "Voglibose", "mechanism", "Guidelines", "conversion", "same times", "intestines", "one tablet", "Optimal Use", "weight gain", "combination", "information", "Adjustments", "Introduction", "Hypoglycemia", "sterisonline", "best results", "sterispharma", "sulfonylureas", "CALL/WHATSAPP", "simple sugars", "Key Component", "treatment plan", "typical dosage", "Administration", "Consistent Use", "Weight Neutral", "low blood sugar", "small intestine", "oral medication", "insulin secretion", "Regular monitoring", "Recommended Dosage", "blood sugar spikes", "effective treatment", "healthcare provider", "complex carbohydrates", "Complementary Therapy", "carbohydrate digestion", "Meal Blood Sugar Levels", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "type 2 diabetes mellitus", "Postprandial Hyperglycemia", "Additional Health Benefits", "other diabetes medications", "comprehensive glycemic control", "other antidiabetic medications", "postprandial blood glucose peaks", "potent alpha-glucosidase inhibitor", "Effective Postprandial Blood Sugar Control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1518, "imageuri": "https://productimages.withfloats.com/actual/667d3145422dd0be26724c0b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3145422dd0be26724c0b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:57:50.904Z", "updatedon": "2024-06-27T09:30:42.497Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vogligold-0-3-/1518", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD 0.3 ", "category": "DIABETIC RANGE", "tags": [ "voglibose 0.3mg price", "voglibose 0.3mg dosage", "voglibose 0.3mg brands in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66619278db9fdd21801ef284", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET TRIO 0.3 ", "description": "SEIZMET TRIO 0.3 \nGlimepiride (2mg), Metformin SR (500mg), Voglibose (0.3mg)\nIntroduction to SEIZMET TRIO 0.3\nSEIZMET TRIO 0.3 is a combination medication that includes Glimepiride 2mg, Metformin Hydrochloride Sustained Release (SR) 500mg, and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Glimepiride, Metformin, and Voglibose, SEIZMET TRIO 0.3 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Glimepiride, Metformin, and Voglibose?\nOverview of Glimepiride\nGlimepiride is a sulfonylurea that helps control blood sugar levels by stimulating the pancreas to release more insulin. It works by closing ATP-sensitive potassium channels in the pancreatic beta cells, leading to insulin secretion.\n\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of SEIZMET TRIO 0.3\nEffective Blood Sugar Management\nTriple Mechanism of Action: Glimepiride stimulates insulin secretion, Metformin improves insulin sensitivity and reduces hepatic glucose production, and Voglibose slows carbohydrate absorption. This comprehensive approach offers robust glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: SEIZMET TRIO 0.3 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, SEIZMET TRIO 0.3 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nImproved Glycemic Control: Voglibose’s action on slowing carbohydrate absorption leads to better control over postprandial spikes, contributing to overall glycemic stability.\nHow to Use SEIZMET TRIO 0.3\nDosage and Administration\nRecommended Dosage: The typical dosage of SEIZMET TRIO 0.3 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin and Voglibose. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take SEIZMET TRIO 0.3 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/seizmet-trio-0-3-133446", "price": 166.9, "discountamount": 50.07, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "3", "day", "body", "Diet", "EMAIL", "Order", "liver", "water", "meals", "amount", "slower", "option", "Action", "Support", "Overview", "pancreas", "readings", "digestion", "biguanide", "Voglibose", "one tablet", "lower rise", "overweight", "Guidelines", "full glass", "neuropathy", "utilization", "Adjustments", "information", "retinopathy", "Optimal Use", "Introduction", "Metformin SR", "SEIZMET TRIO", "best results", "sterisonline", "Reduced Risk", "instructions", "sterispharma", "sulfonylurea", "effectiveness", "CALL/WHATSAPP", "carbohydrates", "Administration", "obese patients", "typical dosage", "treatment plan", "Consistent Use", "Glimepiride 2mg", "small intestine", "Exercise Adjunct", "prolonged effect", "Triple Mechanism", "excellent adjunct", "Weight Management", "weight neutrality", "insulin secretion", "Recommended Dosage", "modest weight loss", "blood sugar control", "Diabetes Management", "individual response", "postprandial spikes", "healthcare provider", "insulin sensitivity", "blood glucose levels", "pancreatic beta cells", "cardiovascular disease", "combination medication", "comprehensive approach", "Fasting Glucose Control", "long-term complications", "robust glycemic control", "lifestyle modifications", "carbohydrate absorption", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "hepatic glucose production", "Additional Health Benefits", "overall glycemic stability", "alpha-glucosidase inhibitor", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "ATP-sensitive potassium channels", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1453, "imageuri": "https://productimages.withfloats.com/actual/6661927b487c46164ce4b1f6.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661927b487c46164ce4b1f6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T10:42:00.595Z", "updatedon": "2024-06-29T07:23:34.909Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//seizmet-trio-0-3-/1453", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SEIZMET TRIO 0.3 ", "category": "DIABETIC RANGE", "tags": [ "SEIZMET TRIO 0.3", "Glimepiride (2mg)", "Metformin SR (500mg)", "Voglibose (0.3mg)", "Glimepiride 2mg side effects", "glimepiride + metformin", "Glimepiride 2mg price", "Glimepiride 2mg Uses in Hindi" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66616410ccd5ce1a107590a0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RAPIGLINIDE VOG 1.0 ", "description": "RAPIGLINIDE VOG 1.0 \nRepaglinide (1mg), Voglibose (0.3mg)\nIntroduction to RAPIGLINIDE VOG 1.0\nRAPIGLINIDE VOG 1.0 is a combination medication that includes Repaglinide 1mg and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Repaglinide and Voglibose, RAPIGLINIDE VOG 1.0 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Repaglinide and Voglibose?\nOverview of Repaglinide\nRepaglinide is a meglitinide analog that helps control blood sugar levels by stimulating the pancreas to produce more insulin. It works by closing ATP-dependent potassium channels in the pancreatic beta-cell membrane, which leads to the opening of calcium channels and insulin release.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of RAPIGLINIDE VOG 1.0\nEffective Blood Sugar Management\nPostprandial Glucose Control: Repaglinide helps reduce blood sugar spikes after meals by stimulating rapid and short-acting insulin secretion. Voglibose complements this by slowing the absorption of carbohydrates, leading to a more gradual increase in blood glucose levels.\nComprehensive Glycemic Control: The combination of these two medications provides a dual mechanism of action that targets both insulin secretion and carbohydrate absorption, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: RAPIGLINIDE VOG 1.0 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, RAPIGLINIDE VOG 1.0 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nHow to Use RAPIGLINIDE VOG 1.0\nDosage and Administration\nRecommended Dosage: The typical dosage of RAPIGLINIDE VOG 1.0 is one tablet taken before each main meal. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet before each meal to enhance its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take RAPIGLINIDE VOG 1.0 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/rapiglinide-vog-1-0-134237", "price": 189.0, "discountamount": 56.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Diet", "rapid", "Order", "EMAIL", "meals", "water", "slower", "action", "Support", "opening", "patients", "pancreas", "readings", "Benefits", "Overview", "Voglibose", "digestion", "main meal", "one tablet", "neuropathy", "full glass", "lower rise", "Guidelines", "information", "Adjustments", "Optimal Use", "Repaglinide", "retinopathy", "sterisonline", "sterispharma", "best results", "Introduction", "Reduced Risk", "CALL/WHATSAPP", "carbohydrates", "effectiveness", "typical dosage", "Consistent Use", "dual mechanism", "treatment plan", "Administration", "insulin release", "RAPIGLINIDE VOG", "small intestine", "two medications", "gradual increase", "calcium channels", "Exercise Adjunct", "excellent adjunct", "Recommended Dosage", "meglitinide analog", "Diabetes Management", "individual response", "healthcare provider", "blood sugar control", "blood glucose levels", "combination medication", "cardiovascular disease", "long-term complications", "lifestyle modifications", "carbohydrate absorption", "complementary mechanisms", "type 2 diabetes mellitus", "stable blood sugar levels", "alpha-glucosidase inhibitor", "Postprandial Glucose Control", "pancreatic beta-cell membrane", "short-acting insulin secretion", "comprehensive glycemic control", "postprandial blood sugar spikes", "ATP-dependent potassium channels", "Effective Blood Sugar Management", "comprehensive blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1415, "imageuri": "https://productimages.withfloats.com/actual/666164117b1fc3f9dd4c947c.png", "tileimageuri": "https://productimages.withfloats.com/tile/666164117b1fc3f9dd4c947c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T07:24:00.417Z", "updatedon": "2024-06-29T10:15:40.38Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/rapiglinide-vog-1-0-/1415", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RAPIGLINIDE VOG 1.0 ", "category": "DIABETIC RANGE", "tags": [ "RAPIGLINIDE VOG 1.0", "Repaglinide (1mg)", "Voglibose (0.3mg)", "Repaglinide 1 mg uses", "Repaglinide 1 mg price", "Repaglinide mechanism of action", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66616318d91d281c30c74f57", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RAPIGLINIDE VOG 0.5 ", "description": "RAPIGLINIDE VOG 0.5 \nRepaglinide (0.5mg), Voglibose (0.3mg)\nIntroduction to RAPIGLINIDE VOG 0.5\nRAPIGLINIDE VOG 0.5 is a combination medication that includes Repaglinide 0.5mg and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Repaglinide and Voglibose, RAPIGLINIDE VOG 0.5 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Repaglinide and Voglibose?\nOverview of Repaglinide\nRepaglinide is a meglitinide analog that helps control blood sugar levels by stimulating the pancreas to produce more insulin. It works by closing ATP-dependent potassium channels in the pancreatic beta-cell membrane, which leads to the opening of calcium channels and insulin release.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of RAPIGLINIDE VOG 0.5\nEffective Blood Sugar Management\nPostprandial Glucose Control: Repaglinide helps reduce blood sugar spikes after meals by stimulating rapid and short-acting insulin secretion. Voglibose complements this by slowing the absorption of carbohydrates, leading to a more gradual increase in blood glucose levels.\nComprehensive Glycemic Control: The combination of these two medications provides a dual mechanism of action that targets both insulin secretion and carbohydrate absorption, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: RAPIGLINIDE VOG 0.5 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, RAPIGLINIDE VOG 0.5 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nHow to Use RAPIGLINIDE VOG 0.5\nDosage and Administration\nRecommended Dosage: The typical dosage of RAPIGLINIDE VOG 0.5 is one tablet taken before each main meal. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet before each meal to enhance its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take RAPIGLINIDE VOG 0.5 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/rapiglinide-vog-0-5-134238", "price": 145.0, "discountamount": 43.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Diet", "rapid", "Order", "EMAIL", "meals", "water", "slower", "action", "Support", "opening", "patients", "pancreas", "readings", "Benefits", "Overview", "Voglibose", "digestion", "main meal", "one tablet", "neuropathy", "full glass", "lower rise", "Guidelines", "information", "Adjustments", "Optimal Use", "Repaglinide", "retinopathy", "sterisonline", "sterispharma", "best results", "Introduction", "Reduced Risk", "CALL/WHATSAPP", "carbohydrates", "effectiveness", "typical dosage", "Consistent Use", "dual mechanism", "treatment plan", "Administration", "insulin release", "RAPIGLINIDE VOG", "small intestine", "two medications", "gradual increase", "calcium channels", "Exercise Adjunct", "excellent adjunct", "Recommended Dosage", "meglitinide analog", "Diabetes Management", "individual response", "healthcare provider", "blood sugar control", "blood glucose levels", "combination medication", "cardiovascular disease", "long-term complications", "lifestyle modifications", "carbohydrate absorption", "complementary mechanisms", "type 2 diabetes mellitus", "stable blood sugar levels", "alpha-glucosidase inhibitor", "Postprandial Glucose Control", "pancreatic beta-cell membrane", "short-acting insulin secretion", "comprehensive glycemic control", "postprandial blood sugar spikes", "ATP-dependent potassium channels", "Effective Blood Sugar Management", "comprehensive blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1413, "imageuri": "https://productimages.withfloats.com/actual/6661631cc40ee9be019a5fd2.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661631cc40ee9be019a5fd2.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T07:19:52.782Z", "updatedon": "2024-06-29T10:18:42.752Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/rapiglinide-vog-0-5-/1413", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RAPIGLINIDE VOG 0.5 ", "category": "DIABETIC RANGE", "tags": [ "RAPIGLINIDE VOG 0.5", "Repaglinide (0.5mg),", "Voglibose (0.3mg)", "voglibose 0.3mg price in india", "voglibose 0.3mg uses", "voglibose 0.3mg dosage" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665ff561db100e1fdc2d90d1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "MOXIDIP 0.3", "description": "MOXIDIP 0.3\nMoxonidine (0.3mg)\nMoxonidine (0.3mg), marketed as MOXIDIP 0.3, is a potent antihypertensive medication primarily used for the treatment of hypertension. Moxonidine works by stimulating receptors in the brain that regulate blood pressure, leading to decreased heart rate and relaxation of blood vessels. This medication is recommended for patients seeking an alternative to traditional hypertension treatments, particularly those who have not responded well to other therapies. Each tablet contains 0.3mg of moxonidine for precise dosage control.\nFor further information:\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nBuy Now: \nhttps://www.sterisonline.com/product/moxidip-0-3-133331\n\n\n\n\n\n", "price": 99.0, "discountamount": 30.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Call", "Email", "0.3mg", "brain", "tablet", "product", "MOXIDIP", "WhatsApp", "patients", "receptors", "relaxation", "heart rate", "Moxonidine", "alternative", "information", "sterisonline", "sterispharma", "blood vessels", "blood pressure", "other therapies", "precise dosage control", "potent antihypertensive medication", "traditional hypertension treatments" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1324, "imageuri": "https://productimages.withfloats.com/actual/665ff5629a0a3c2c06fd33ef.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ff5629a0a3c2c06fd33ef.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-05T05:19:29.829Z", "updatedon": "2024-06-05T05:19:29.829Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/moxidip-0-3/1324", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "MOXIDIP 0.3", "category": "CARDIOLOGYRANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665ee8be7b387b17ecbcbde3", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": " SACUBRIGHT 200 ", "description": "SACUBRIGHT 200 \nSacubitril (97mg), Valsartan (103mg)\nSACUBRIGHT 200 is a combination medication containing two active ingredients: Sacubitril (97mg) and Valsartan (103mg). This combination is designed to provide dual inhibition of the renin-angiotensin-aldosterone system (RAAS) for the treatment of heart failure with reduced ejection fraction (HFrEF).\n\nSacubitril is a neprilysin inhibitor, while Valsartan is an angiotensin II receptor blocker (ARB). Together, they work synergistically to improve cardiovascular outcomes in patients with HFrEF by targeting different pathways involved in the pathophysiology of heart failure.\n\nNeprilysin is an enzyme responsible for the degradation of natriuretic peptides, which play a crucial role in regulating blood pressure and fluid balance. By inhibiting neprilysin, Sacubitril increases the levels of natriuretic peptides, leading to vasodilation, natriuresis, and diuresis, which helps reduce blood pressure, preload, and afterload on the heart.\n\nValsartan, as an ARB, blocks the effects of angiotensin II, a vasoconstrictor and stimulator of aldosterone secretion. By antagonizing the angiotensin II type 1 (AT1) receptors, Valsartan dilates blood vessels, reduces blood pressure, and attenuates the deleterious effects of angiotensin II on cardiac remodeling and fibrosis.\n\nSACUBRIGHT 200 is indicated for the treatment of symptomatic HFrEF in patients with New York Heart Association (NYHA) class II-IV heart failure. Clinical studies have demonstrated that this combination therapy reduces the risk of cardiovascular death and hospitalization for heart failure compared to traditional therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) alone.\n\nAs with any medication, SACUBRIGHT 200 may cause side effects, including hypotension, hyperkalemia, renal impairment, and angioedema. Patients should be monitored regularly for these adverse effects, especially during initiation and dose titration.\n\nOverall, SACUBRIGHT 200 represents an innovative approach to the management of HFrEF, offering superior efficacy and cardiovascular benefits compared to standard therapy. However, it should only be used under the supervision of a healthcare professional experienced in the management of heart failure and in accordance with established treatment guidelines.\n\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/sacubright-200-134307\n\n\n\n", "price": 740.0, "discountamount": 222.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "ARB", "risk", "RAAS", "EMAIL", "Order", "levels", "diuresis", "fibrosis", "patients", "Valsartan", "stimulator", "initiation", "angioedema", "SACUBRIGHT", "accordance", "management", "Sacubitril", "natriuresis", "degradation", "information", "supervision", "hypotension", "sterisonline", "sterispharma", "hyperkalemia", "vasodilation", "side effects", "crucial role", "CALL/WHATSAPP", "fluid balance", "blood vessels", "dose titration", "AT1) receptors", "blood pressure", "dual inhibition", "adverse effects", "pathophysiology", "hospitalization", "vasoconstrictor", "standard therapy", "renal impairment", "Clinical studies", "symptomatic HFrEF", "superior efficacy", "different pathways", "cardiac remodeling", "combination therapy", "deleterious effects", "innovative approach", "traditional therapy", "treatment guidelines", "neprilysin inhibitor", "cardiovascular death", "natriuretic peptides", "angiotensin II type 1", "aldosterone secretion", "two active ingredients", "combination medication", "cardiovascular outcomes", "cardiovascular benefits", "healthcare professional", "reduced ejection fraction", "New York Heart Association", "angiotensin receptor blockers", "angiotensin II receptor blocker", "NYHA) class II-IV heart failure", "renin-angiotensin-aldosterone system", "angiotensin-converting enzyme (ACE) inhibitors" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1279, "imageuri": "https://productimages.withfloats.com/actual/665ee8c06030c166b1a41ef3.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ee8c06030c166b1a41ef3.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T10:13:18.717Z", "updatedon": "2024-06-04T10:13:18.717Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/-sacubright-200-/1279", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Sacubitril (97mg), Valsartan (103mg)", "category": "CARDIOLOGYRANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-09-25T10:46:50.098Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }